PLSE pulsebiosciences.com Profit After Tax

Corporate emblem and logo of pulsebiosciences.com (PLSE)

The current market value of Pulse Biosciences, Inc. (PLSE) shown on this chart correlates with market expectations for new product approvals while management optimizes internal cycles. The indicator stands at -0.08. Pulse Biosciences, Inc. (PLSE) generates revenue by supplying gentle skin pathology removal systems to clinics and oncologists. Meanwhile, device assembly is outsourced to third-party EMS providers, although the company retains ownership of all technology patents.

Net Income: Pulse Corp (PLSE) for 07/04/2022 - 10/30/2026

Financial and market metric breakdowns for Pulse Biosciences (PLSE)

- market value and analyst target forecast:
Stock Price Pulse Medical|PLSE - Price Target Chart
- market capitalization data:
Market Valuation Pulse Medical|PLSE - Enterprise Value
- issuer book value statistics:
Net Asset Value per Share Pulse Biosciences|PLSE - Company Net Assets|Market Capitalization to Book Value Ratio pulsebiosciences.com|PLSE - Cumulative Company Assets
- debt burden and liquidity indicators:
Aggregate Debt to Capital Pulse Biosciences, Inc.|PLSE - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Pulse Biosciences Inc|PLSE - Company Aggregate Debts|Debt to Book Value Pulse Medical|PLSE - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Pulse Biosciences|Quick Liquidity Indicator pulsebiosciences.com
- company profitability and valuation multiples indicators:
PLSE - Net Profit
Fundamental valuation:PLSE, Pulse Medical
Flagship merchandise of Pulse Corp

A portfolio analyst utilizes this tool to separate fundamental leaders from volatile assets. The metric captures final net income, allowing for an assessment of business resilience against market fluctuations. For Pulse Biosciences, Inc. (PLSE), this indicator reflects the monetization efficiency of nano-pulse developments relative to R&D expenditures. High costs associated with recruiting bioengineers directly impact final margins. The trend in the company's financial profit serves as an indicator of the transition from the research stage to profitability.

Key competitors

Dexcom CGM (DXCM) - Net Profit|Company Net Income Penumbra, Inc.|novanta.com - Profit After Tax|Net Profit HAE|INSP - Company Net Income|PROCEPT BioRobotics Inc - Net Income|Net Profit CONMED Inc. CNMD|INMD: Net Income|picardmedical.com - Profit After Payment of Taxes|SRDX: Net Profit|SENS - Net Financial Result|NPCE (NeuroPace Corp) - Net Profit|Net Income Tactile Systems Technology Inc. (TCMD)|Net Income SNWV (Sanuwave Health Inc)|OM (outsetmedical.com) - Final Profit|Company Net Income Electromed ELMD|LNSR - Net Income|AVITA Medical, Inc - Net Profit|Company Net Income Profound Medical Corp.|BDMD: Net Profit|Company Profit EDAP|APYX (Apyx Medical Corp) - Net Profit|IceCure Medical, Ltd. (ICCM) - Net Financial Result|Net Profit LUNG|Net Income telabio.com TELA|Net Profit CTSO (CytoSorbents Corporation)|Net Profit sensushealthcare.com SRTS|ZYXI - Company Net Income|ECOR: Company Net Income|RBOT (vicarioussurgical.com) - Net Income|Inspira Technologies - Final Profit|ICU (SeaStar Medical Holding) - Net Profit|Company Net Income IRIDEX Corp. IRIX|Company Net Income Intelligent Bio Solutions (INBS)|beyondair.net (XAIR) - Annual Net Income|Profusa, Inc. - Net Income|Net Profit STRATA Skin Sciences Inc. SSKN|GlucoTrack - Net Profit|Net Financial Result NanoVibronix Inc. NAOV|Venus Concept (VERO) - Company Net Income|Profit After Tax NUWE (Nuwellis Inc)|Company Net Income Aethlon|Net Income TransEnterix (ASXC)|Net Profit AVGR|BSGM - Company Net Income|Company Net Income Cutera CUTR|KNW: Company Profit|NARI: Net Income|Nevro Medical - Profit After Payment of Taxes|reshapelifesciences.com (RSLS) - Company Net Income|Profit After Tax SILK (silkroadmed.com)